Clinical Trial Update: A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients [Phase 3]

View source ↗

Summary

A Phase 3 randomized study comparing 0.5 mg ranibizumab to laser therapy in Chinese patients with diabetic macular edema completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Diabetic Macular Edema, Visual Impairment | Phase 3 | Status: COMPLETED | Results posted: 2019-02-01